Delcath Systems, Inc.: Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Breast Cancer
Delcath Systems (Nasdaq: DCTH) said the first patient was dosed in its Phase 2 DELUMA trial of HEPZATO plus standard of care versus standard of care alone for liver-dominant HER2-negative metastatic breast cancer. The randomized study will enroll about 90 patients at 20+ sites in the US and Europe, with hepatic progression-free survival as the primary endpoint.
How this was made
The 30-second read
Why it matters
The milestone advances the DELUMA Phase 2 randomized trial in liver-dominant HER2-negative metastatic breast cancer, using physician’s choice SOC (eribulin, vinorelbine, or capecitabine) and hepatic progression-free survival as the primary endpoint.
Market read
For DCTH, the actionable takeaway is trial execution progress (first dose) and the defined endpoint framework, which can influence near-term sentiment and positioning ahead of enrollment updates.
What to watch
Key overhangs remain enrollment speed, site activation, and whether hepatic progression-free survival shows differentiation versus SOC.
Background
Delcath is developing HEPZATO (melphalan via hepatic delivery) for liver-dominant metastatic cancers; HEPZATO KIT is already approved for metastatic uveal melanoma in the US.
Ticker impact
Delcath says the first patient was dosed in its Phase 2 DELUMA trial of HEPZATO for liver-dominant metastatic breast cancer.
Likely modest positive bias, with follow-through dependent on enrollment pace and interim safety/efficacy updates.
The article discloses a concrete clinical milestone (first dose) plus trial design details (randomized, SOC comparator, endpoints), but provides no new clinical results or regulatory decision.
Market effects
Adds incremental momentum for interventional oncology and liver-directed delivery platforms, but impact is company-specific.
No direct regional macro linkage; trial site activity spans US and Europe.
Limited global read-across since it is an early execution milestone without efficacy outcomes.
Counterpoint
First-patient dosing can be routine and may not translate into meaningful value until safety and efficacy signals emerge.
Key entities
- companyDelcath Systems, Inc.
Interventional oncology company running the DELUMA Phase 2 trial of HEPZATO.
- productHEPZATO
Melphalan-based hepatic delivery therapy evaluated in combination with SOC.
- clinical_trialDELUMA (NCT06875128)
Phase 2 randomized trial comparing HEPZATO plus SOC versus SOC alone in liver-dominant metastatic breast cancer.
- siteEuropean Institute of Oncology (IEO)
Milan site where the first patient was dosed.
